Jiangsu STMed Technology Co., Ltd.
PrivateLast Round
Series D
Dec 26, 2019
Total Funding Raised
$119.29M
Company Overview
Jiangsu STMed Technology Co., Ltd. operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series D round in December 2019.
Jiangsu STMed Technology Co., Ltd. is a medical technology company that develops and manufactures advanced life-support equipment, including ECMO systems and related cardiovascular surgical products.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Jiangsu STMed Technology Co., Ltd. Comparables
Compare Jiangsu STMed Technology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MagAssist | 96% | |
| Chinabridge (Shenzhen) Medical Technology Co., Ltd. | 94% | |
| Lifemotion Medical Technology | 87% |
For institutional investors. Book with your work email.
Jiangsu STMed Technology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Dec 26, 2019 | ||||
| Series A | Aug 1, 2014 |
For institutional investors. Book with your work email.
Jiangsu STMed Technology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| China Reform Holdings Corporation Ltd. | Series D |
| Jiangsu Ruihua Investment Holding Group | Series D |
| Nanjing Yangzi State-owned Investment Group | Series D |
| Lilly Asia Ventures | Series D |
| Guoxin Science and Technology Innovation Fund Management Co., Ltd. | Series D |
| SB China Capital | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 26, 2019
$114M round led by China Reform Holdings Corporation.
- Aug 1, 2014
$5M round led by Beijing Beilu Pharmaceutical Co., Ltd.
For institutional investors. Book with your work email.
Jiangsu STMed Technology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Jiangsu STMed Technology Co., Ltd.'s valuation, stock price, and market status.
Is Jiangsu STMed Technology Co., Ltd. a public or private company?
Jiangsu STMed Technology Co., Ltd. is a private company.
What is the current stock price of Jiangsu STMed Technology Co., Ltd.?
Jiangsu STMed Technology Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Jiangsu STMed Technology Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Jiangsu STMed Technology Co., Ltd. worth (valuation)?
Valuation information for Jiangsu STMed Technology Co., Ltd. is not publicly available.
Can I buy Jiangsu STMed Technology Co., Ltd. stock?
Jiangsu STMed Technology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Jiangsu STMed Technology Co., Ltd.'s last funding round?
Jiangsu STMed Technology Co., Ltd.'s most recent funding round was Series D on December 26, 2019.
Who are the main investors in Jiangsu STMed Technology Co., Ltd.?
Key investors in Jiangsu STMed Technology Co., Ltd. include China Reform Holdings Corporation Ltd..
Will Jiangsu STMed Technology Co., Ltd. IPO soon?
No public IPO plans have been announced for Jiangsu STMed Technology Co., Ltd..
How can I track Jiangsu STMed Technology Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Jiangsu STMed Technology Co., Ltd.'s shares on secondary markets.